Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer

NCT00031837 is registered in ClinicalTrials.gov with Gary Morrow as lead sponsor.

NCT NCT00031837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Controlled Multicenter Study of the Effect of Dalteparin on Quality of Life in Unresectable Pancreatic Cancer
Lead sponsor
Gary Morrow
Phase
Phase 3
Overall status
Terminated
Start date
October 31, 2002
Completion date
December 31, 2006
Enrollment
400 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, thromboembolism